Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A A Joy

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2001
Letrozole in second-line therapy of advanced breast cancer: more questions than answersJ R Mackey, A A Joy
Current Oncology (Toronto, Ont.)|June 20, 2007
Adjuvant trastuzumab: progress, controversies, and the steps aheadA A Joy, J R Mackey
Current Oncology (Toronto, Ont.)|January 1, 2008
Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding in CanadaS Verma, S Sehdev, A A Joy
Current Oncology (Toronto, Ont.)|December 31, 2015
Oncologist heal thyself: hallmarks of happinessC Jacobs, M Clemons, A A Joy
Current Oncology (Toronto, Ont.)|August 19, 2016
Will oncologists applaud the Paris Accord? Time to rethink global mega-conferencesC Jacobs, A A Joy, M Clemons
Current Oncology (Toronto, Ont.)|November 2, 2017
What we learned in kindergarten: five tips for collaboration in oncologyA Arnaout, A A Joy, M Juliao, et al.
Current Oncology (Toronto, Ont.)|June 23, 2016
Real-world adjuvant TAC or FEC-D for HER2-negative node-positive breast cancer in women less than 50 years of ageS Lupichuk, D Tilley, X Kostaras, et al.
Current Oncology (Toronto, Ont.)|April 8, 2015
Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesA A Joy, M Ghosh, R Fernandes, et al.
Current Oncology (Toronto, Ont.)|April 29, 2016
Training the trainer: five practical considerations for your first five years in practiceC Jacobs, A A Joy, M Clemons, et al.
Current Oncology (Toronto, Ont.)|June 19, 2018
Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the linesA Matutino, A A Joy, C Brezden-Masley, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2001
Letrozole in second-line therapy of advanced breast cancer: more questions than answersJ R Mackey, A A Joy
Current Oncology (Toronto, Ont.)|June 20, 2007
Adjuvant trastuzumab: progress, controversies, and the steps aheadA A Joy, J R Mackey
Current Oncology (Toronto, Ont.)|January 1, 2008
Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding in CanadaS Verma, S Sehdev, A A Joy
Current Oncology (Toronto, Ont.)|December 31, 2015
Oncologist heal thyself: hallmarks of happinessC Jacobs, M Clemons, A A Joy
Current Oncology (Toronto, Ont.)|August 19, 2016
Will oncologists applaud the Paris Accord? Time to rethink global mega-conferencesC Jacobs, A A Joy, M Clemons
Current Oncology (Toronto, Ont.)|November 2, 2017
What we learned in kindergarten: five tips for collaboration in oncologyA Arnaout, A A Joy, M Juliao, et al.
Current Oncology (Toronto, Ont.)|June 23, 2016
Real-world adjuvant TAC or FEC-D for HER2-negative node-positive breast cancer in women less than 50 years of ageS Lupichuk, D Tilley, X Kostaras, et al.
Current Oncology (Toronto, Ont.)|April 8, 2015
Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesA A Joy, M Ghosh, R Fernandes, et al.
Current Oncology (Toronto, Ont.)|April 29, 2016
Training the trainer: five practical considerations for your first five years in practiceC Jacobs, A A Joy, M Clemons, et al.
Current Oncology (Toronto, Ont.)|June 19, 2018
Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the linesA Matutino, A A Joy, C Brezden-Masley, et al.
Pageof 3